Chronic allograft nephropathy is a devastating complication of kidney transplantation that is responsible for a significant proportion of graft loss. This complication is characterized by a progressive decline in kidney function, which is not attributable to a specific cause. Many risk factors exist for the development of chronic allograft nephropathy, including donor-, recipient-, and transplant-related factors (eg, use of calcineurin inhibitors and acute rejection episodes), as well as comorbid conditions such as hypertension and hyperlipidemia. There is no definitive treatment for this complication; management has focused on minimization or withdrawal of calcineurin inhibitors in conjunction with addition of sirolimus or mycophenolate mofetil. Alterations in the immunosuppressive regimen must be done cautiously, as precipitating acute rejection will cause further damage to the allograft. Optimal control of blood pressure, particularly with the use of agents such as angiotensin II receptor blockers, in conjunction with management of dyslipidemia may be effective concurrent therapies in patients with chronic allograft nephropathy.
Get full access to this article
View all access options for this article.
References
1.
URREA; UNOS.2002Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1992–2001. Available at: http://www.optn.org/data/annualReport.asp. Accessed November 21, 2003.
2.
CeckaJM. The UNOS scientific renal transplant registry. In: CeckaJMTerasakiPI, eds. Clinical Transplants 1999.Los Angeles, Calif: UCLA Tissue Typing Laboratory; 1999:1–21.
3.
PonticelliC. Progression of renal damage in chronic rejection. Kidney Int.2000;57(suppl 75):S62–S70.
4.
RacusenLCSolezKColvinRB. The Banff 97 working classification of renal allograft pathology. Kidney Int.1999;55:713–723.
5.
KasiskeBLKalilRSNLeeHSRaoKV. Histopathologic findings associated with a chronic, progressive decline in renal allograft function. Kidney Int.1991;40:514–524.
6.
KriegerNRBeckerBNHeiseyDM. Chronic allograft nephropathy uniformly affects recipients of cadaveric, non-identical living-related, and living-unrelated grafts. Transplantation.2003;75:1677–1682.
Meier-KriescheHUOjoAOHansonJA. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation.2000;70:1098–1100.
9.
SijpkensYWJDoxiadisNIIVan KemenadeFJ. Chronic rejection with or without transplant vasculopathy. Clin Transplant.2003;17:163–170.
10.
SolezKVincentiFFiloRS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation.1998;66:1736–1740.
11.
IsoniemiHNurminenMTikkanenMJ. Risk factors predicting chronic rejection of renal allografts. Transplantation.1994;57:68–72.
12.
CampistolJMInigoPLariosSBescosMOppenheimerF. Role of transforming growth factor-b1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant.2001;16(suppl 1):114–116.
13.
NicholsonMLBaileyEWilliamsSHarrisKPGFurnessPN. Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation.1999;68:236–241.
14.
MurphyGJWallerJRSandfordRSFurnessPNNicholsonML. Randomized clinical trial of the effect of microemulsion cyclosporine and tacrolimus on renal allograft fibrosis. Br J Surg.2003;90:680–686.
15.
WeirMRWardMTBlahutSA. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int.2001;59:1567–1573.
16.
DudleyCRK, for the MMF “Creeping Creatinine” Study Group. MMF substitution for CsA is an effective and safe treatment of chronic allograft dysfunction; results of a multicenter randomized controlled study [abstract 41]. Am J Transplant.2002;2(suppl 3):148.
17.
KahanBDKnightRSchoenbergL. Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience. Transplant Proc.2003; 35(suppl 3A):25S–34S.
18.
OberbauerRKreisHJohnsonRWG. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation.2003;76:364–370.
19.
CitterloFScataMCVioliP. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc.2003;35:1292–1294.
20.
SaundersRNBicknellGRNicholsonML. The impact of cyclosporine dose reduction with or without the addition of Rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation.2003; 75:772–780.
21.
RuizJCCampistolJMMotaA. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplant Proc.2003;35:1669–1670.
22.
AmmJMRamamurthyGDegalaA. Rapamycin substitution for calcineurin inhibitors in renal transplant recipients with chronic allograft nephropathy: A report of 57 cases [abstract 235]. Am J Transplant.2003;3(suppl 5):211.
23.
PodderHStepkowskiSMNapoliKL. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol.2001;12:1059–1071.
24.
NashanB. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit.2002;24:53–58.
25.
LutzJZouHLiuSAntusBHeemannU. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation.2003;76:508–515.
26.
MuirheadNHouseAHollombyDJJevnikarAM. Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy. Transplant Proc.2003;35:2412–2414.
27.
StigantCECohenJViveraMZaltzmanJS. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy. Am J Kidney Dis.2000;35:58–63.
28.
OmotoKTanabeKTokumotoT. Use of candesartan cilexitil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation.2003;76: 1170–1174.
29.
LinJValeriAMMarkowitzGS. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation.2002;73:783–788.
30.
El-AgroudyAEHassanNAFodaMA. Effect of angiotensin II receptor blocker on plasma levels of TGF-β1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol.2003;23:300–306.
31.
CampistolJMInigoPJimenezW. Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy. Kidney Int.1999;56:714–719.
32.
InigoPCampistolJMLarioS. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-[beta]1 plasma levels in a crossover trial in renal transplant recipients. Transplantation.2001;12:822–827.
33.
KatznelsonSKobashigawaJA. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int.1995; 52:S112–115.
34.
MurphyGJTahaRWindmillDCMetcalfeMNicholsonML. Influence of aspirin on early allograft thrombosis and chronic allograft nephropathy following renal transplantation. Br J Surg.2001;88:261–266.
